MapLight Therapeutics, Inc. (MPLT)
NASDAQ: MPLT · Real-Time Price · USD
15.95
+3.64 (29.57%)
Jul 29, 2026, 3:13 PM EDT - Market open
MapLight Therapeutics Employees
MapLight Therapeutics had 133 employees as of December 31, 2025. The number of employees increased by 70 or 111.11% compared to the previous year.
Employees
133
Change
70
Growth
111.11%
Revenue / Employee
n/a
Profits / Employee
-$1,499,850
Market Cap
723.26M
Employees Chart
| Date | Employees | Change (1Y) | Growth (1Y) |
|---|---|---|---|
| Dec 31, 2025 | 133 | 30 | 29.13% |
| Sep 30, 2025 | 114 | - | - |
| Jun 30, 2025 | 109 | 35 | 47.30% |
| Mar 31, 2025 | 103 | 29 | 39.19% |
| Mar 31, 2024 | 74 | - | - |
Related Stocks
| Company Name | Employees |
|---|---|
| Valneva SE | 674 |
| ProKidney | 231 |
| Cabaletta Bio | 158 |
| Kyverna Therapeutics | 129 |
| Ocugen | 116 |
| Cybin | 100 |
| Prothena Corporation | 67 |
| Inhibikase Therapeutics | 35 |
MPLT News
- 1 day ago - MapLight Therapeutics price target lowered to $25 from $40 at Craig-Hallum - TheFly
- 1 day ago - MapLight Therapeutics price target lowered to $24 from $43 at Canaccord - TheFly
- 1 day ago - MapLight downgraded to Equal Weight from Overweight at Morgan Stanley - TheFly
- 1 day ago - MapLight Therapeutics price target lowered to $26 from $45 at H.C. Wainwright - TheFly
- 2 days ago - MPLT Investors Have Opportunity to Join MapLight Therapeutics, Inc. Fraud Investigation with SBS Law - Business Wire
- 2 days ago - MapLight's schizophrenia drug fails once-daily test, shares plunge - Reuters
- 2 days ago - MapLight Therapeutics Transcript: Study result - Transcripts
- 2 days ago - MapLight Therapeutics Slides: Study result - Filings